Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress

Earnings Call Insights: Sage Therapeutics (SAGE) Q1 2025 Management View CEO Barry Greene highlighted a strong start to 2025 with significant milestones for ZURZUVAE, the first oral treatment approved for postpartum depression (PPD). Over 3,000 prescriptions were shipped in Q1 2025, marking a 22% increase.